An experimental Alzheimer’s disease drug developed by Eisai and Biogen succeeded in a large Phase 3 trial, raising its chances for regulatory approval and boosting a long-running hypothesis about how to treat the most common cause of dementia.
Trial results showed treatment with the drug, called lecanemab, slowed clinical decline by 27% compared to a placebo over an 18-month period, the companies said in a Tuesday statement. Alzheimer’s symptoms were measured on a commonly used rating scale that assesses cognitive and functional performance.
